<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860807</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA035054-01</org_study_id>
    <secondary_id>R01DA035054</secondary_id>
    <nct_id>NCT01860807</nct_id>
  </id_info>
  <brief_title>Trial of Ibudilast for Methamphetamine Dependence</brief_title>
  <acronym>IBUD ph II</acronym>
  <official_title>Randomized Trial of Ibudilast for Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test the safety and potential efficacy of ibudilast to&#xD;
      treat methamphetamine dependence. The study hypotheses are that ibudilast will reduce&#xD;
      methamphetamine use and increase treatment retention more than placebo among patients seeking&#xD;
      treatment for methamphetamine dependence. As HIV infection is a common complication of&#xD;
      methamphetamine dependence, half of the participants will be HIV positive and the study will&#xD;
      assess whether ibudilast also improves HIV related outcomes (e.g. medication adherence, CD4&#xD;
      count, risk behaviors).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ibudilast (IBUD) is a macrophage migration inhibitory factor (MIF) and phosphodiesterase&#xD;
      (PDE)-4 and -10 inhibitor at peak clinical exposures (Rolan, Hutchinson et al. 2009) that&#xD;
      increases glial cell line-derived neurotrophic factor (GDNF) expression (Mizuno, Kurotani et&#xD;
      al. 2004) and reduces microglial activation (Suzumura, Ito et al. 1999; Suzumura, Ito et al.&#xD;
      2003), including HIV-induced glial activation (Kiebala and Maggirwar 2011). IBUD&#xD;
      significantly reduces methamphetamine (MA) prime- and stress-induced reinstatement of MA&#xD;
      seeking in rats (Beardsley, Shelton et al. 2010) and has multiple effects that may make it an&#xD;
      effective treatment for MA dependence including amelioration of dopaminergic and&#xD;
      neuroinflammatory dysfunction. Multiple studies implicate glial cells in a variety of&#xD;
      neurodegenerative diseases (Hirsch and Hunot 2009; Sidoryk-Wegrzynowicz, Wegrzynowicz et al.&#xD;
      2011) including MA dependence and HIV infection (Nath 2010). Activated glial cells secrete&#xD;
      pro-inflammatory mediators (Minghetti, Ajmone-Cat et al. 2005) that may exacerbate MA-induced&#xD;
      dopaminergic dysfunction. Glial cells also produce neurotrophic factors, including GDNF,&#xD;
      which may ameliorate dopaminergic dysfunction (Pascual, Hidalgo-Figueroa et al. 2008). Thus,&#xD;
      IBUD may be an effective medication for MA dependence due to its modulation of glial cell&#xD;
      activation resulting in amelioration of dopaminergic and neurocognitive dysfunction and&#xD;
      improved treatment outcomes in MA dependence. IBUD may also have unique effects in HIV&#xD;
      positive MA users as it may additionally block the degradation of neuronal integrity seen in&#xD;
      HIV infection (Chana, Everall et al. 2006; Dash, Gorantla et al. 2011).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methamphetamine Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>End of treatment methamphetamine abstinence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Ibudilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibudilast 50 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibudilast</intervention_name>
    <arm_group_label>Ibudilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older;&#xD;
&#xD;
          2. meet DSM-IV-TR criteria for MA dependence (SCID verified);&#xD;
&#xD;
          3. a MA-positive urine drug screen at one or more visit during the two week lead-in&#xD;
             period;&#xD;
&#xD;
          4. seeking treatment for MA problems;&#xD;
&#xD;
          5. willing and able to comply with study procedures;&#xD;
&#xD;
          6. provide written informed consent;&#xD;
&#xD;
          7. English speaking&#xD;
&#xD;
          8. reside within 35 miles of the clinical research site; and&#xD;
&#xD;
          9. if female of childbearing potential, not pregnant or lactating and willing to use a&#xD;
             medically reliable method of birth control during the trial (e.g., birth control&#xD;
             pills, Depo-Provera, and/or condoms with spermicide).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. a medical condition that, in the study physician's judgment, may interfere with safe&#xD;
             study participation (e.g., active TB; unstable cardiac, renal, or liver disease;&#xD;
             uncontrolled hypertension; unstable diabetes);&#xD;
&#xD;
          2. CD4 count &lt; 50 cells/mm3 (suggestive of advanced HIV infection)&#xD;
&#xD;
          3. AST, ALT, or GGT &gt; 3 times upper normal limit;&#xD;
&#xD;
          4. A corrected QT of &gt; 450 msecs in men or &gt; 460 msec in women on at least two ECGs&#xD;
             during the baseline period, or clinical risk factors for Torsades de Pointes (e.g.&#xD;
             (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), or requiring&#xD;
             ongoing treatment with concomitant medication(s) with established risk of Torsades de&#xD;
             Pointes (e.g. Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine,&#xD;
             Chlorpromazine, Cisapride, Citalopram, Clarithromycin, Disopyramide, Dofetilide,&#xD;
             Domperidone, Droperidol, Erythromycin, Flecainide, Halofantrine, Haloperidol,&#xD;
             Ibutilide, Levomethadyl, Mesoridazine, Methadone, Moxifloxacin, Pentamidine, Pimozide,&#xD;
             Probucol, Procainamide, Quinidine, Sotalol, Sparfloxacin, Terfenadine, Thioridazine,&#xD;
             Vandetanib);&#xD;
&#xD;
          5. current ongoing treatment with psychotropic medications (e.g., antidepressants,&#xD;
             antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics);&#xD;
&#xD;
          6. a neurological disorder (e.g., organic brain disease, dementia) or a medical condition&#xD;
             which would make study agent compliance difficult or which would compromise informed&#xD;
             consent;&#xD;
&#xD;
          7. a major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar&#xD;
             disorder) as assessed by the SCID;&#xD;
&#xD;
          8. attempted suicide in the past 3 years and/or serious suicidal intention or plan in the&#xD;
             past year as assessed by the C-SSRS;&#xD;
&#xD;
          9. currently on prescription medication that is contraindicated for use with IBUD&#xD;
             including alpha or beta agonists, theophylline, or other sympathomimetics;&#xD;
&#xD;
         10. current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by&#xD;
             DSM-IV-TR;&#xD;
&#xD;
         11. alcohol dependence within the past year;&#xD;
&#xD;
         12. greater than one urine specimens during the lead-in with a riboflavin concentration of&#xD;
             &lt; 900 ng/ml as assessed via UV fluorescence;&#xD;
&#xD;
         13. a history of sensitivity to IBUD; or&#xD;
&#xD;
         14. any other circumstances that, in the opinion of the investigators, would compromise&#xD;
             participant safety;&#xD;
&#xD;
         15. current participation in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Heinzerling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Vine Street Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <results_first_submitted>January 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <last_update_submitted>January 6, 2019</last_update_submitted>
  <last_update_submitted_qc>January 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Keith Heinzerling</investigator_full_name>
    <investigator_title>Associate Professor in Residence</investigator_title>
  </responsible_party>
  <keyword>methamphetamine</keyword>
  <keyword>ibudilast</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01860807/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ibudilast</title>
          <description>Ibudilast 50 mg twice daily&#xD;
Ibudilast</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo twice daily&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibudilast</title>
          <description>Ibudilast 50 mg twice daily&#xD;
Ibudilast</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo twice daily&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="9.0"/>
                    <measurement group_id="B2" value="42.8" spread="10.5"/>
                    <measurement group_id="B3" value="41.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline methamphetamine use on 26 or more days per month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methamphetamine Use</title>
        <description>End of treatment methamphetamine abstinence</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibudilast</title>
            <description>Ibudilast 50 mg twice daily&#xD;
Ibudilast</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo twice daily&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Methamphetamine Use</title>
          <description>End of treatment methamphetamine abstinence</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 week medication treatment period and 4 week post-treatment follow-up period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibudilast</title>
          <description>Ibudilast 50 mg twice daily&#xD;
Ibudilast</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo twice daily&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study did not determine if ibudilast may help patients who have stopped methamphetamine use prior to starting medication</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Keith Heinzerling MD</name_or_title>
      <organization>UCLA</organization>
      <phone>310-319-4700</phone>
      <email>kheinzerling@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

